A/DT
novel/JJ
mutation/NN
in/IN
the/DT
coding/VBG
sequence/NN
of/IN
the/DT
FY*B/NN
allele/NN
of/IN
the/DT
Duffy/NN
chemokine/NN
receptor/NN
gene/NN
is/VBZ
associated/VBN
with/IN
an/DT
altered/JJ
erythrocyte/NN
phenotype/NN
./.

The/DT
Duffy/NN
blood/NN
group/NN
system/NN
is/VBZ
of/IN
clinical/JJ
and/CC
biological/JJ
significance/NN
./.
=====
Antibodies/NNS
to/TO
Duffy/NN
antigens/NNS
are/VBP
responsible/JJ
for/IN
some/DT
cases/NNS
of/IN
transfusion/NN
incompatibility/NN
and/CC
newborn/JJ
hemolytic/JJ
disease/NN
./.
=====
The/DT
Duffy/NN
protein/NN
is/VBZ
a/DT
receptor/NN
for/IN
the/DT
Plasmodium/NN
vivax/NN
erythrocyte-binding/JJ
protein/NN
and/CC
is/VBZ
also/RB
a/DT
receptor/NN
for/IN
various/JJ
chemokines/NNS
(/(
thus/RB
renamed/VBN
Duffy/NN
Antigen/NN
Receptor/NN
for/IN
Chemokines/NNS
[/(
DARC/NN
]/)
)/)
./.
=====
The/DT
two/CD
Duffy/NN
polymorphic/JJ
antigens/NNS
,/,
Fya/NN
and/CC
Fyb/NN
(/(
coded/VBN
by/IN
the/DT
FY*A/NN
and/CC
FY*B/NN
alleles/NNS
)/)
,/,
are/VBP
present/JJ
on/IN
erythrocyte/NN
membranes/NNS
./.
=====
The/DT
Fy(a-b-)/NN
phenotype/NN
is/VBZ
the/DT
predominant/JJ
one/CD
in/IN
populations/NNS
of/IN
black/JJ
people/NN
and/CC
also/RB
occurs/VBZ
in/IN
other/JJ
populations/NNS
,/,
including/VBG
some/DT
non-Ashkenazi/JJ
Jewish/JJ|NN
groups/NNS
./.
=====
The/DT
Fy(a-b-)/NN
phenotype/NN
has/VBZ
been/VBN
associated/VBN
with/IN
a/DT
mutation/NN
in/IN
the/DT
FY*B/NN
promoter/NN
at/IN
the/DT
GATA/NN
box/NN
that/WDT
abolishes/VBZ
the/DT
expression/NN
of/IN
erythrocyte/NN
Duffy/NN
protein/NN
./.
=====
We/PRP
describe/VBP
here/RB
a/DT
novel/JJ
mutation/NN
,/,
present/JJ
in/IN
the/DT
FY*B/NN
coding/VBG
sequence/NN
(/(
271C/NN
-->/TO
T/NN
)/)
,/,
that/WDT
is/VBZ
associated/VBN
with/IN
some/DT
Fy(b-)/NN
phenotypes/NNS
among/IN
non-Ashkenazi/JJ
Jews/NNS
and/CC
among/IN
Brazilian/JJ
blacks/NNS
./.
=====
The/DT
mutation/NN
is/VBZ
present/JJ
in/IN
Fy(b-)/NN
individuals/NNS
,/,
who/WP
have/VBP
wild-type/JJ
FY*B/NN
GATA/NN
and/CC
carry/VBP
the/DT
previously/RB
described/VBN
304G/NN
-->/TO
A/NN
substitution/NN
./.
=====
The/DT
271C/NN
-->/TO
T/NN
and/CC
304G/NN
-->/TO
A/NN
can/MD
be/VB
identified/VBN
by/IN
restriction/NN
enzyme-generated/JJ
restriction/NN
fragment/NN
length/NN
polymorphisms/NNS
./.
=====
The/DT
271C/NN
-->/TO
T/NN
substitution/NN
represents/VBZ
a/DT
considerable/JJ
change/NN
in/IN
chemical/JJ
nature/NN
(/(
Arg91/NN
-->/TO
Cys/NN
)/)
,/,
one/CD
which/WDT
may/MD
affect/VB
the/DT
antigenic/JJ
determinants/NNS
of/IN
DARC/NN
,/,
and/CC
thus/RB
be/VB
of/IN
clinical/JJ
significance/NN
./.
=====
The/DT
mutation/NN
may/MD
have/VB
implications/NNS
for/IN
some/DT
physiological/JJ
roles/NNS
of/IN
DARC/NN
and/CC
be/VB
of/IN
interest/NN
in/IN
malaria/NN
research/NN
and/CC
in/IN
studies/NNS
of/IN
population/NN
genetics/NNS
./.